1. Monitoring the Progress of Clinical Trials in a Network Setting: Experience from the National Drug Abuse Treatment Clinical Trials Network P. VanVeldhuisen 1, C. Allen 1, A. Wahle 1, L. Lu 1, C. Cushing 2, P. Wakim 2, B. Tai 2 1 NIDA Data and Statistics Center 2, The EMMES Corporation, Rockville, MD; 2 NIDA Center for the Clinical Trials Network, Bethesda, MD Abstract The National Drug Abuse Treatment Clinical Trials Network (CTN), established by the National Institute on Drug Abuse (NIDA), has developed a comprehensive set of web- based standardized Trial Progress Reports (TPR) to use as a management tool to effectively monitor the progress of on-going clinical trials in real-time. These reports track the progress of each protocol within the CTN from the date of first randomization to final closeout and publication of main results. The content includes areas from all aspects of the clinical trials: recruitment, retention, availability of primary outcome, treatment exposure (i.e., the number of medication or placebo doses actually taken, or psychosocial therapy sessions actually attended, divided by the corresponding number that a participant is expected to take or attend), quality assurance, and regulatory. Most of the reports in the TPR are updated daily and all reports are web-based and are available on a secure website to provide real-time access to critical protocol information. The TPR provides both a big-picture view of the NIDA CTN protocols and a very detailed view to meet the needs of the varied audience, which include: NIDA as the Sponsor and the Executive Committee as the CTN Governance Body Lead Investigative Team as the Study Leaders Audience  The sponsor and study leadership to assess the overall progress of multiple on-going protocols.  The protocol lead teams to monitor their respective protocols in order to identify areas of concern on an individual site level.  The investigators and staff at each participating community treatment provider (CTP) within a protocol to monitor their individual site’s performance against other sites. Metrics have been developed for key protocol components to provide feedback at a glance on the progress of the protocols. These metrics have been assigned color- codes, where green denotes good performance, yellow where problem areas are identified, and red where poor performance is noted and remedial actions required. The TPR has allowed the NIDA CTN leadership and protocol teams to monitor and intervene in the critical aspects of recruitment, retention, data quality, and treatment implementation to improve upon the overall quality of the research being conducted. Community Treatment Providers (CTPs) as the Participating Sites NIDA’s Center for the Clinical Trials Network and the CTN Executive Committee use the TPR to assess the overall progress of multiple on-going protocols. Example presentations below include protocol-specific monthly recruitment in the CTN and overall protocol performance statistics. Protocol performance statistics show color- coded boxes across various monitored areas, where green denotes good performance, yellow where problem areas are identified, and red where poor performance is noted and remedial actions required. The Lead Investigative Team of the clinical trial uses the TPR to monitor overall progress of the protocol and to identify areas of concern on an individual site level. Example presentations below include expected number of randomizations compared with actual, and site-level performance with green, yellow and red color designations. Investigators and staff at participating sites use the TPR to monitor their individual site’s performance against other sites. Example presentations below include recruitment, treatment exposure, primary outcome availability, and long-term follow-up. Dash Board View Expected vs. Actual Randomizations, Overall Expected vs. Actual Randomizations, By CTP CTP1CTP2 CTP3 CTP5 CTP7 CTP9CTP10 CTP8 CTP6 CTP4 Key Features of TPR Timing Updated daily to allow real-time information on status of protocols Format of tables Consistent format and performance criteria to allow comparisons across protocols Individual reports and consolidated reports available from dash board All in pdf format No treatment-specific or outcome data (beyond availability) providedCTN-9996CTN-9997CTN-9998CTN-9999 Acknowledgement This research was supported by the National Institute on Drug Abuse, National Drug Abuse Treatment Clinical Trials Network, National Institutes of Health, through Contract No. HHSN271200900034C.